Antibody format and drug release rate determine the therapeutic activity of noninternalizing antibody-drug conjugates

Molecular Cancer Therapeutics

Volumn 14, Issue 11, 2015, Pages 2606-2612

  Gébleux, Rémy ^a   Wulhfard, Sarah ^b   Casi, Giulio ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b PHILOCHEM AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; F8 MONOCLONAL ANTIBODY; MAYTANSINE; MONOCLONAL ANTIBODY; SIP(F8)-SS-DM1;

ANIMAL; BODY WEIGHT; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; DRUG RELEASE; FEMALE; FLUORESCENCE MICROSCOPY; HAMSTER; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROCEDURES; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BODY WEIGHT; CELL LINE, TUMOR; CHO CELLS; CHROMATOGRAPHY, LIQUID; CRICETINAE; CRICETULUS; DRUG LIBERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; IMMUNOCONJUGATES; MASS SPECTROMETRY; MAYTANSINE; MICE; MICROSCOPY, FLUORESCENCE; NEOPLASMS, EXPERIMENTAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84958150818     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0480     Document Type: Article

References (44)

1. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998;58:1195-201.
2. Krall N, Scheuermann J,Neri D. Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries. Angew Chem Int Ed Engl 2013;52:1384-402.
3. van der Veldt AAM, Hendrikse NH, Smit EF, Mooijer MPJ, Rijnders AY, Gerritsen WR, et al. Biodistribution and radiation dosimetry of C-11-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imag 2010; 37:1950-8.
4. van der Veldt AAM, Lubberink M, Mathijssen RHJ, Loos WJ, Herder GJM, Greuter HN, et al. Toward prediction of efficacy of chemotherapy: A proof of concept study in lung cancer patients using C-11 docetaxel and positron emission tomography. Clin Cancer Res 2013;19:4163-73.
5. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. In: Caskey CT, editor. Annu Rev Med 2013. p. 15-29.
6. Chari RVJ, MillerML, WiddisonWC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 2014;53:3796-827.
7. Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: current and future developments. MAbs 2009;1: 247-53.
8. Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389-97.
9. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
10. Ballantyne A, Dhillon S. Trastuzumab Emtansine: first global approval. Drugs 2013;73:755-65.
11. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013;12:329-33.
12. Bander NH. Antibody-drug conjugate target selection: critical factors. Methods Mol Biol 2013;1045:29-40.
13. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009;69:2358-64.
14. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5: 436-46.
15. Bernardes GJL, Casi G, Truessel S, Hartmann I, Schwager K, Scheuermann J, et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl 2012;51:941-4.
16. Casi G, Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 2012;161:422-8.
17. Perrino E, Steiner M, Krall N, Bernardes GJ, Pretto F, Casi G, et al. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res 2014;74:2569-78.
18. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008;122:2405-13.
19. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-70.
20. Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 2015; 33:733-5.
21. McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 2006;19:299-307.
22. Zuberbuhler K, Palumbo A, Bacci C, Giovannoni L, Sommavilla R, Kaspar M, et al. A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells. Protein Eng Des Sel 2009;22:169-74.
23. Bernardes GJL, Steiner M, Hartmann I, Neri D, Casi G. Site-specific chemical modification of antibody fragments using traceless cleavable linkers. Nat Protoc 2013;8:2079-89.
24. Pasche N, Woytschak J, Wulhfard S, Villa A, Frey K, Neri D. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol 2011;154:84-92.
25. Strickland S, Smith KK, Marotti KR. Hormonal induction of differentiation in teratocarcinoma stem cells: generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell 1980;21:347-55.
26. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85.
27. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
28. Shen BQ, Xu KY, Liu LN, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibodydrug conjugates. Nat Biotechnol 2012;30:184-9.
29. Drake PM, Albers AE, Baker J, Banas S, Barfield RM, Bhat AS, et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem 2014;25:1331-41.
30. Tian F, Lu Y,Manibusan A, Sellers A, Tran H, Sun Y, et al. Ageneral approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A 2014; 111:1766-71.
31. Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, et al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug Chem 2015;26:650-9.
32. Kim KM, McDonagh CF, Westendorf L, Brown LL, Sussman D, Feist T, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 2008;7:2486-97.
33. Steiner M, Hartmann I, Perrino E, Casi G, Brighton S, Jelesarov I, et al. Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature. Chem Sci 2013; 4:297-302.
34. Cleland WW. Dithiothreitol, a new protective reagent for SH groups. Biochemistry 1964;3:480-2.
35. Cohen R, Vugts DJ, Visser GWM, Stigter-van Walsum M, Bolijn M, Spiga M, et al. Development of novel ADCs: conjugation of tubulysin analogues to trastuzumabmonitored by dual radiolabeling. Cancer Res 2014;74:5700-10.
36. Carlsson J, Eriksson V, Stenerlow B, Lundqvist H. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy. Eur J Nucl Med Mol Imaging 2006;33:1185-95.
37. Warnecke A, Fichtner I, Sass G, Kratz F. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch Pharm 2007;340:389-95.
38. Rothberg JM, Bailey KM, Wojtkowiak JW, Ben-Nun Y, Bogyo M, Weber E, et al. Acid-mediated tumor proteolysis: contribution of cysteine cathepsins. Neoplasia 2013;15:1111-23.
39. Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999;17:375-8.
40. Ostermann E, Garin-Chesa P, Heider KH, KalatM, Lamche H, Puri C, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 2008;14:4584-92.
41. Krall N, Pretto F, DecurtinsW, Bernardes GJ, Supuran CT, Neri D. A smallmolecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl 2014;53:4231-5.
42. Felber AE, Dufresne MH, Leroux JC. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv Drug Deliv Rev 2012;64:979-92.
43. Gutbrodt KL, Casi G, Neri D. Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol Cancer Ther 2014; 13:1772-6.
44. List T, Casi G, Neri D. A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity. Mol Cancer Ther 2014; 13:2641-52.